Harvest One (TSXV:HVT) (OTCQX:HRVOF), through it’s wholly-owned subsidiary United Greeneries Ltd. (“United Greeneries”) today announced that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart.

Under the terms of the agreement, Harvest One will supply Shoppers Drug Mart with Satipharm branded medical cannabis products. The products will be sold online, as Canadian regulations restrict the sale of medical cannabis in retail pharmacies.


Harvest One Announces Supply Agreement with Shoppers Drug Mart (CNW Group/Harvest One Cannabis Inc.)
Harvest One Announces Supply Agreement with Shoppers Drug Mart (CNW Group/Harvest One Cannabis Inc.)
Harvest One Announces Supply Agreement with Shoppers Drug Mart (CNW Group/Harvest One Cannabis Inc.)
Harvest One Announces Supply Agreement with Shoppers Drug Mart (CNW Group/Harvest One Cannabis Inc.)
Harvest One Announces Supply Agreement with Shoppers Drug Mart (CNW Group/Harvest One Cannabis Inc.)
Harvest One Announces Supply Agreement with Shoppers Drug Mart (CNW Group/Harvest One Cannabis Inc.)

This marks the first time that Satipharm branded cannabis will be available for purchase.  Working in conjunction with Shoppers Drug Mart in an effort to help consumers make specific, educated decisions about their purchases, Satipharm will be available in a continuum of products, each colour coded to indicate their place on the progression from the high THC of SatiWhite™ to the high CBD of SatiPurple™.  At launch, United Greeneries will produce and ship an Indica variety of SatiSilver™ and a hybrid variety of SatiGreen™.

“We are incredibly proud to be working with Shoppers Drug Mart to supply them with our premium, indoor grown cannabis under the Satipharm health and wellness brand” said Grant Froese, CEO of Harvest One. “We see this supply agreement as a further step towards fulfilling our vision of being a vertically integrated house of brands in the cannabis health, wellness, and self-care sector.  We continue to expand our capacity to support our growing brand portfolio which includes our recently announced transaction with Delivra as well as our existing brands Dream Water, Satipharm, Royal High, and Captain’s Choice” he added.

ABOUT HARVEST ONE CANNABIS INC.

Harvest One is a global cannabis company that develops and provides innovative lifestyle and wellness products to consumers and patients in regulated markets around the world. The Company’s range of lifestyle solutions is designed to enhance quality of life. Shareholders have significant exposure to the entire cannabis value chain through three wholly-owned subsidiaries: United Greeneries, a Licensed Producer; Satipharm (medical and nutraceutical); and Dream Water Global (consumer), and a minority interest in Burb Cannabis (retail operations). For more information, please visit www.harvestone.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

For further information: Colin Clancy, Investor Relations, cclancy@harvestone.com, 1-877-915-7934; Will Stewart, Senior Vice President, Corporate and Public Affairs, WStewart@HarvestOne.com, 416-899-9422

Click here to connect with Harvest One (TSXV:HVT) for an Investor Presentation. 

Source: www.newswire.ca

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less